<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Megger, Dominik Andre</dc:creator>
  <dc:creator>Abou-Eid, Shadi</dc:creator>
  <dc:creator>Zülch, Birgit</dc:creator>
  <dc:creator>Sitek, Barbara</dc:creator>
  <dc:date>2018-09-20</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Chemotherapeutic treatment regimens often take advantage of synergistic effects of  drug combinations. Anticipating that synergistic effects on the cell biological level likely  manifest on the proteome level, the analysis of proteome modulations represents an  appropriate strategy to study drug combinations on a molecular level. More  specifically, the detection of single proteins exhibiting synergistic abundance changes  could be helpful to shed light on key molecules, which contribute in mechanisms  facilitating the synergistic interaction and therefore represent potential targets for  specific therapeutic approaches. In the reported study we aimed to provide evidence  for this assumption and investigated the drug combination of cisplatin and the  neddylation inhibitor MLN4924 in HCT-116 cells via cell biological analyses and mass  spectrometry-based quantitative proteomics. From 1789 proteins quantified with two  unique peptides, activated RNA polymerase II transcriptional coactivator p15 (SUB1)  was highlighted as the most synergistically regulated protein using a synergistic  scoring approach. Western blotting and analyses of cellular processes associated with  this protein (DNA damage, oxidative stress and apoptosis) revealed supporting  evidence for the synergistic regulation. Whereas the distinct role of SUB1 in the  investigated drug combination needs to be elucidated in future studies, the presented  results demonstrated the benefit and feasibility of synergistic scoring of proteome  alterations to highlight proteins that likely contribute to the underlying molecular  mechanisms of synergistic effects. Data are available via ProteomeXchange with  identifier PXD009185.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/307315</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307315/files/abo_sas.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307315/files/abo_sas_sm.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307315/files/abo_sas_sm2.txt</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307315/files/abo_sas_sm3.txt</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307315/files/abo_sas_sm4.txt</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1039/C8MO00115D</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Molecular Omics. - 2018, vol. 14, no. 6, p. 450–457</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Systematic analysis of synergistic proteome modulations in a drug combination of cisplatin and MLN4924</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
